Stock Events

Stock Events

Geron

€1.41

143

+€0.07+5.02% Today

Statistics

Day High

1.41

Day Low

1.41

52W High

1.65

52W Low

0.91

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

6MayExpected

Q4 2025

Next

-0.04

-0.03

-0.03

-0.02

Expected EPS

-0.0170678

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GON.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotechnology company focused on developing novel therapies, including for hematologic malignancies, which competes with Geron's focus on blood cancers.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for various cancers, directly competing with Geron's cancer therapies.

Bristol-Myers Squibb

Bristol Myers Squibb offers a wide range of cancer treatments, including those for hematologic cancers, making it a direct competitor to Geron.

Novartis is a global healthcare company with a significant presence in oncology, including research in treatments for blood cancers, competing with Geron's development focus.

Pfizer has a diverse oncology portfolio, including therapies for breast and hematologic cancers, positioning it as a competitor to Geron.

AbbVie, with its acquisition of Pharmacyclics, has expanded its oncology portfolio, including treatments for hematologic malignancies, competing with Geron's therapeutic area.

Gilead Sciences

Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in cell therapies for cancer, including hematologic malignancies, competing with Geron's focus.

Merck & Co. is involved in the development of cancer treatments, including immunotherapies that could be used in treating hematologic cancers, making it a competitor to Geron.

Roche, with its strong focus on oncology and a broad portfolio of cancer treatments, including for blood cancers, competes with Geron in the oncology space.

About

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Show more...

CEO

Mr. Harout Semerjian

Employees

258

Country

United States

ISIN

US3741631036

Listings

0 Comments

Share your thoughts

FAQ

What is Geron stock price today?▼

The current price of GON.MU is €1.41 EUR — it has increased by +5.02% in the past 24 hours. Watch Geron stock price performance more closely on the chart.

What is Geron stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Geron stocks are traded under the ticker GON.MU.

How many employees does Geron have?▼

As of May 06, 2026, the company has 258 employees.

In which sector is Geron located?▼

Geron operates in the Manufacturing sector.

When did Geron complete a stock split?▼

Geron has not had any recent stock splits.

Where is Geron headquartered?▼

Geron is headquartered in Foster City, United States.